Mercialys (XPAR:MERY) Research & Development: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MERY Mercialys SA XPAR:MERY
78 GF Score
Price €11.78
GF Value €11.15
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Mercialys Research & Development?

Mercialys XPAR:MERY -0.84% 78 Research & Development is €0.0 Mil as of Jun. 2026. GuruFocus rates XPAR:MERY with a GF Score™ of 78/100 and a GF Value™ of €11.15 (Fairly Valued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Mercialys's Research & Development for the six months ended in Jun. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €0.0 Mil.

Mercialys  (XPAR:MERY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mercialys Research & Development Related Terms

Mercialys Research & Development Historical Data

* Premium members only.

The historical data trend for Mercialys's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercialys Research & Development Chart

Mercialys Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mercialys Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:MERY
78GF Score
Mercialys SA XPAR:MERY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercialys Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Mercialys (XPAR:MERY) has a Research & Development of €0.0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Mercialys and its competitors.
Is Mercialys' Research & Development too high?
Mercialys' current Research & Development is €0.0 Mil. Overall, Mercialys has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mercialys' Research & Development compare to SPG and O?
Mercialys' Research & Development of €0.0 Mil can be compared against companies in the REITs industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a REITs company?
A good Research & Development depends on the REITs industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Mercialys and its competitors. Mercialys's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercialys stock overvalued right now?
Based on GuruFocus' analysis, Mercialys (XPAR:MERY) is currently considered Fairly Valued. The stock's GF Value™ is €11.15, compared to a current price of €11.78 — trading 5.7% above its estimated fair value. The current Research & Development is €0.0 Mil. Mercialys' overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Mercialys (XPAR:MERY), the current Research & Development is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercialys (XPAR:MERY) Overvalued in 2026?

Based on GuruFocus' analysis, Mercialys stock appears to be overvalued. The current stock price of €11.78 is trading 5.7% above its estimated GF Value™ of €11.15. GuruFocus considers Mercialys to be Fairly Valued.

Key valuation signals for XPAR:MERY:

  • Research & Development: €0.0 Mil
  • GF Value™: €11.15 vs. price of €11.78 (5.7% above fair value)
  • GF Score™: 78/100 with 9 warning signs

No single metric tells the full story. See the XPAR:MERY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercialys Business Description

Industry Real EstateREITs
Other Exchanges MERYp:UK0IQU:UKM8Y:Germany
Address 16-18, rue du Quatre-Septembre, Paris, FRA, 75002
Mercialys SA is a real estate company based in France and Europe. The firm and its subsidiaries own and manage shopping centers in France. The company has developed and promoted the G LA GALLERIE brand for all its shopping centers. The company mainly operates in France. The company is based on sustainable value creation through investments in medium-sized properties.
78GF Score

Get the complete analysis for XPAR:MERY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.78
Price
€11.15
GF Value